Fig. 4
Correlation between soluble factors and immune cells anti-cancer activity A. Clinical characteristics and treatment response of the 11 patients evaluated divided by dose level. Comparison of median serum levels of soluble CEACAM-5 (B), CEACAM-6 (C) and MICA (D) in patients with stable (SD) and progressive disease (PD) at different time points. Serum levels of soluble factors were detected using commercially available ELISA kits. Statistically significant difference between groups was determined by 2way ANOVA. Differences in median serum levels of soluble CEACAM-5, CEACAM-6, and MICA in patients with SD compared to patients with PD were not statistically significant. E–F. Comparison of the percentage of NKG2D+/CD107a+ and NKp46+ NK cells in patients with stable (SD) and progressive disease (SD) at different time points by flow cytometry analysis. NKG2D+/CD107a+ and NKp46+ NK cells were gated from CD56+/CD16+ population from PBMCs. Data are presented as median of percentage of viable cells expressing NK markers. Positivity was determined by using fluorescence-minus-one controls. G. Comparison of the percentage of circulating CD4+/NEO-201+ Tregs at different time points in patients treated with NEO-201 DL 1.5 by flow cytometry analysis. CD4+/NEO-201+ population was gated from PBMCs. Data are presented as percentage of viable cells. Positivity was determined by using fluorescence-minus-one controls